Wuhan YZY Biopharma Co Ltd
Company Profile
Business description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer, and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas. The company has designed and developed various clinical-stage candidate drug pipelines, such as M701 (EpCAM CD3 bispecific antibody), Y101D, Y150, Y2019 (RBD dimer subunit SARS-CoV-2 vaccine), M802, and Y400 (VEGFxANG2 bispecific antibody) for the treatment of different cancer and age-related complications. Geographically, the company derives all of its revenue from the People's Republic of China (PRC).
Contact
No. 666 Gaoxin Road
Building C2-1, Guanggu Biocity
East Lake High Tech Development Zone
Hubei Province
Wuhan
CHNT: +86 2782668988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
113
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,591.10 | 19.70 | 0.23% |
CAC 40 | 7,864.44 | 46.05 | -0.58% |
DAX 40 | 23,999.17 | 123.23 | -0.51% |
Dow JONES (US) | 41,859.09 | 1.35 | -0.00% |
FTSE 100 | 8,739.26 | 47.20 | -0.54% |
HKSE | 23,679.99 | 135.68 | 0.58% |
NASDAQ | 18,925.73 | 53.09 | 0.28% |
Nikkei 225 | 37,200.92 | 215.05 | 0.58% |
NZX 50 Index | 12,619.01 | 43.24 | -0.34% |
S&P 500 | 5,842.01 | 2.60 | -0.04% |
S&P/ASX 200 | 8,366.10 | 17.40 | 0.21% |
SSE Composite Index | 3,382.96 | 2.77 | 0.08% |